Sign in
Taking people in South KoreaNo phase

Long-term follow-up of people treated with Kymriah for blood cancers

Follows people with B-cell leukemia or lymphoma treated with Kymriah over time.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, and Ulsan, South KoreaSee the 8 sites
Trial code
Registry title
Long-term Follow up Local Registry Study of Kymriah in South Korea
Status
Recruiting
People taking part
500 people, planned
Started
12 Mar 2025
Expected to end
30 Dec 2039
Type of study
Observational
Treatments tested
  • Tisagenlecleucel
Record updated
30 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with B-cell blood cancers who received tisagenlecleucel (Kymriah) in routine care in South Korea. It follows them over time to check long-term safety.

Age
0 to 100 years
Sex
All sexes can join.
Disease stage
B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma or follicular lymphoma.
Earlier treatment
Must have received a tisagenlecleucel infusion in the commercial setting, a managed access program or another pathway.

Main reasons for not taking part

  • Already in, or going to be in, the Novartis long-term follow-up protocol CCTL019A2205B
  • Has not consented to data collection

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS)
  • Consented to data collection

Who cannot take part

  • Patients who are enrolled or will be enrolled in the Novartis long term follow-up protocol CCTL019A2205B

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 100 years old?

Where in South Korea

  • Bundang Gu, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • BusanHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Gyeonggi-do, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • IncheonHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • JeollanamHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Seongnam-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • UlsanHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.

The group in the trial

  • Tisagenlecleucel

    Patients who have been treated with tisagenlecleucel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea
Plain-language title
Long-term follow-up of people treated with Kymriah for blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06785818, who can take part
Record updated
30 July 2026